Byoung-Mog Kwon

This inventor holds 17 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Korea Research Institute of Bioscience and Biotechnology, Korea Institute of Science and Technology, Vspharmtech. Active years: 1998-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Byoung-Mog Kwon. Retrieved from https://idiyas.com/inventor/byoung-mog-kwon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 1)

% Patents Active = 52.9

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 7.4

ph-index = 5

Forward Citations = 132(Granted Patents)

Location History:

Taejon, KR (2005)
Daejon, KR (2010)
Daejeon, KR (1998 - 2024)

Company Filing History:

11 out of 334

Korea Research Institute of Bioscience and Biotechnology

patents

5 out of 2,248

Korea Institute of Science and Technology

Years Active: 1998-2026

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12721842 - Cinnamamide derivatives and use thereof (2026-09-01),

2. 11945779 - Inhibitors of cancer metastasis through inhibiting migration and invasion of cancer cells (2024-04-02),

3. 9580399 - Geranyl flavonoid derivative with improved water solubility, a method for preparing the same, and a method for treating cancer using the same (2017-02-28),

4. 9486490 - Composition for preventing or treating cancer containing extracts of artocarpus altilis fruits, leaves, or stems, or fractions thereof as active ingredients (2016-11-08),

5. 8367736 - Anticancer composition comprising obovatol or obovatal (2013-02-05),

6. 8183405 - Obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient (2012-05-22),

7. 7799811 - Agent for prevention and treatment of cancer comprising oxadiazole urea compound obstructing activity of stat (2010-09-21),

8. 7250432 - Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers (2007-07-31),

9. 6949682 - Cinnamaldehyde derivatives inhibiting growth of tumor cell and regulating cell cycle, preparations and pharmaceutical compositions thereof (2005-09-27),

10. 6808724 - Artemisolide compound isolated from the aerial parts of Artemisia sylvatica, isolation method, and use thereof (2004-10-26),

11. 6620938 - Compounds that inhibit GRB2-SHC binding and process for preparing same (2003-09-16),

12. 6387948 - 8-Acetylarteminolide and process for preparing same (2002-05-14),

13. 6165984 - Naringin and naringenin as inhibitors of acyl (2000-12-26),

14. 5877208 - Naringin and naringenin as 3-hydroxy-3-methylglutaryl CoA(HMG-CoA) (1999-03-02),

15. 5801254 - Arteminolide derivatives and process for the manufacture thereof (1998-09-01),

Title: Byoung-Mog Kwon: Pioneering Innovations in Cancer Treatment

Introduction

Byoung-Mog Kwon is an esteemed inventor hailing from Daejeon, South Korea. With a remarkable portfolio of 16 patents, he has made significant contributions to the field of medical innovations, particularly in cancer research. His work focuses on creating novel pharmaceutical compositions aimed at preventing and treating cancer metastasis.

Latest Patents

Among his latest patents are groundbreaking inventions that highlight his dedication to combating cancer. One notable patent involves inhibitors of cancer metastasis through inhibiting migration and invasion of cancer cells. This innovation presents a pharmaceutical composition for preventing or treating cancer metastasis, which includes a novel compound as an active ingredient, known for its efficacy in inhibiting cancer cell migration and invasion.

Another significant invention is a geranyl flavonoid derivative with improved water solubility. This patent outlines a method for preparing this compound and its application in cancer treatment. The invention demonstrates the novel geranyl flavonoid's ability to inhibit the expression of STAT3 target protein, which has been linked to cancer cell growth inhibition across various cancer cell lines. Additionally, it shows promise in significantly reducing tumor size and weight in vivo, indicating its potential as an effective therapeutic agent against cancer.

Career Highlights

Throughout his career, Byoung-Mog Kwon has worked with prominent institutions, including the Korea Research Institute of Bioscience and Biotechnology and the Korea Institute of Science and Technology. His innovative spirit and dedication have led to numerous advancements in cancer therapeutics, positioning him as a key figure in the biotechnology field.

Collaborations

Byoung-Mog Kwon has collaborated with esteemed colleagues such as Kwang-Hee Son and Dong Cho Han. These partnerships have fostered a dynamic environment for innovation, blending diverse expertise to push the boundaries of medical research and development.

Conclusion

In summary, Byoung-Mog Kwon's contributions to cancer research through his innovative patents illustrate his commitment to advancing medical science for the betterment of society. His work not only enhances the understanding of cancer treatment but also serves as a beacon of hope for patients facing this daunting illness.

Profile summary based on public USPTO records.